Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HRH2 | P25021 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2295823 | 1.00 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2MAPK1KMT2ATSHR | |
| SCHEMBL2296318 | 0.87 | GRIN2B (0.51) | ALDH1A1MAPK1KMT2ATSHRLMNA | |
| SCHEMBL2294991 | 0.87 | GRIN2B (0.51) | ALDH1A1MAPK1KMT2ATSHRLMNA | |
| SCHEMBL2298916 | 0.87 | POLB (0.47) | ALDH1A1SMN1; SMN2KMT2ATSHRLMNA | |
| SCHEMBL2298151 | 0.87 | POLB (0.47) | ALDH1A1SMN1; SMN2KMT2ATSHRLMNA | |
| SCHEMBL2299421 | 0.87 | USP30 (0.41) | ALDH1A1SMN1; SMN2KMT2APOLBPDE4B | |
| SCHEMBL2294982 | 0.87 | USP30 (0.41) | ALDH1A1SMN1; SMN2KMT2APOLBPDE4B | |
| SCHEMBL31198730 | 0.84 | MEN1 (0.55) | SMN1; SMN2KMT2APDE4BGRIN2B | |
| SCHEMBL28807580 | 0.84 | EPHX2 (0.43) | ALDH1A1KMT2APOLBGAA | |
| Hydrochloric Acid SCHEMBL27861758 | 0.84 | GRIN2B (0.43) | KMT2ATSHRPDE4BGRIN2BRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110257392-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | SANOFI-AVENTIS (FR) | 2011-10-20 | — | — | US | disclosed |
| US-20110251385-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | SANOFI-AVENTIS (FR) | 2011-10-13 | — | — | US | disclosed |
| US-7994315-B2 | Intermediate compound for synthesizing pharmaceutical agent and production method thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257392-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | MAPT, PSEN1, PSEN2 | ALDH1A1 1251/4885SMN1; SMN2 849/4885MAPK1 28/4885 |
| US-20110251385-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | MAPT, PSEN1, PSEN2 | ALDH1A1 1251/4885SMN1; SMN2 849/4885MAPK1 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.